We are live on ! Find out more
BJCM

Blue Jay Capital Management Portfolio holdings

AUM $147M
1-Year Est. Return 64.18%
This Fund
S&P 500
This Quarter Est. Return
+11.67%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$147M
AUM Growth
-$56.7M
Cap. Flow
-$65.5M
Cap. Flow %
-44.61%
Top 10 Hldgs %
58.43%
Holding
30
New
9
Increased
3
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$7.05M
2
QGEN icon
Qiagen
QGEN
+$6.94M
3
SNN icon
Smith & Nephew
SNN
+$6.77M
4
BKD icon
Brookdale Senior Living
BKD
+$6.22M
5
ICLR icon
Icon
ICLR
+$5.6M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$12.7M
2
GMED icon
Globus Medical
GMED
+$11.8M
3
QGENF
QIAGEN NV
QGENF
+$11.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.9M
5
BCR
CR Bard Inc.
BCR
+$9.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRX
26
DELISTED
Akorn Inc
AKRX
– –
-300,000
Closed -$7.22M
DERM
27
DELISTED
Dermira, Inc.
DERM
– –
-210,000
Closed -$7.16M
CELG
28
DELISTED
Celgene Corp
CELG
– –
-72,902
Closed -$9.07M
BCR
29
DELISTED
CR Bard Inc.
BCR
– –
-37,419
Closed -$9.3M
QGENF
30
DELISTED
QIAGEN NV
QGENF
– –
-390,000
Closed -$11.3M
1
2

Similar funds

BCM
Breithorn Capital Management New York $141M AUM 41.82% 1-Year Est. Return
RJA
Robshaw & Julian Associates Williamsville, New York $140M AUM 13.69% 1-Year Est. Return
RP
Ridgegate Proprietary Sydney, Australia $154M AUM 25.47% 1-Year Est. Return
ACPVT
ABS Capital Partners V Trust Baltimore, Maryland $123M AUM
SFA
Staton Financial Advisors Charlotte, North Carolina $118M AUM 11.07% 1-Year Est. Return
KL
Kinsight LLC Birmingham, Alabama $176M AUM 17.21% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $107M AUM 37.25% 1-Year Est. Return
KFS
Kissinger Financial Services Hunt Valley, Maryland $100M AUM 6.22% 1-Year Est. Return

Blue Jay Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Blue Jay Capital Management held 30 positions worth $147M, down 28% from $203M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Blue Jay Capital Management withdrew a net $65.5M in Q2 2017, closing 10 positions and reducing 8 holdings. Its most notable exit was Biogen, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.

Against the trend, Blue Jay Capital Management opened a new position in Neurocrine Biosciences worth $6.68M.

  • Blue Jay Capital Management's largest Q2 2017 buy was Neurocrine Biosciences: 145,303 shares worth $6.68M.
  • Blue Jay Capital Management added most to Wright Medical Group Inc in Q2 2017, an estimated $403K increase.
  • Blue Jay Capital Management's biggest Q2 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $4.09M.
  • Blue Jay Capital Management fully exited Biogen in Q2 2017, selling an estimated $12.7M.
  • Blue Jay Capital Management's ten largest holdings make up 58% of its $147M portfolio in Q2 2017.
  • Blue Jay Capital Management opened 9 new positions and closed 10 in Q2 2017.
  • Blue Jay Capital Management's portfolio value fell 28% quarter-over-quarter to $147M.

Based on Blue Jay Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.